Global Anti-Rheumatics Market Size, Share, Forecast Report, 2020-2027

The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026.

Rheumatoid arthritis is a medical condition, which is marked by the presence of warm, swollen, and painful joints. The condition mostly affects both wrists and hands of a person. This medical condition is associated with pain, which worsens over time. The treatment for this condition is achieved by using different drugs, which are known as anti-rheumatics. Furthermore, these drugs are also used to modify the course of the medical condition. For instance, disease-modifying anti-rheumatics drugs are a type of anti-rheumatics drugs that slow down the progression of this disease. Moreover, drugs such as non-steroidal anti-inflammatory drugs are also used in the treatment for rheumatoid arthritis.
The major factors that fuel the growth of the global anti-rheumatics market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of the anti-rheumatics market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of the market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the anti-rheumatics market.

Anti-rheumatics Market Segmentation

The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatics drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

Segment Review

According to drug class, the disease modifying anti-rheumatics drugs occupied the largest anti-rheumatics market share in 2018, owing to their action on the medical condition. For instance, DMARDs act on the underlying medical condition rather than acting on the symptoms. Furthermore, the nonsteroidal anti-inflammatory drugs segment is expected to register the fastest growth during the forecast period, owing to the surge in incidences of rheumatoid arthritis associated with pain in the joints.
By type, the prescription-based drugs segment occupied the largest share, owing to rise in the number of specialized hospitals worldwide as the medical condition requires treatment from a specialized medical professional. Furthermore, the over-the-counter drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in awareness related to treatment options available for rheumatoid arthritis. Moreover, easy availability of NSAIDs over-the-counter is another major factor that contributes to the growth of the anti-rheumatics market.
By region, North America accounted for the major anti-rheumatics market share in 2018 and is expected to continue this trend owing to, easy availability of the anti-rheumatics. Moreover, surge in geriatric population in the region is another major factor that fuels the growth of anti-rheumatics market in North America. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of anti-rheumatics. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.
The global anti-rheumatics market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Pfizer, Inc., Johnson & Johnsons, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Celegene Corporations, MedImmune, LLC, Takeda Pharmaceutical Company Ltd., Biogen Inc., Celltrion Inc., and Amgen Inc.

Key Benefits for Stakeholders:

• This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The anti-rheumatics market forecast is studied from 2019 to 2026. 
• The market size and estimations are based on comprehensive analysis of key developments in the industry. 
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments:

By Drug Class

• Disease Modifying Anti-rheumatics Drugs (DMARD's)
• Nonsteroidal Anti-inflammatory Drugs (NSAID's)
• Corticosteroids
• Uric Acid Drugs
• Others

By Type

• Prescription-Based Drugs
• Over-the-Counter Drugs

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany 
  • France 
  • UK 
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan 
  • China 
  • India 
  • Australia 
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil 
  • Saudi Arabia 
  • South Africa
  • Rest of LAMEA